News COVAID-studie trekt werkzaamheid van reumageneesmiddelen bij gehospitaliseerde COVID-19-patienten in twijfel 15/03/2021 Een studie gecoördineerd door het UZ Gent en gefinancierd door het KCE Trials Programme van het Federaal Kenniscentrum voor de Gezondheidszorg (KCE) toont aan dat de reumageneesmiddelen tocilizumab, siltuximab en anakinra geen impact hebben bij de behandeling van Belgische gehospitaliseerde COVID-19-patiënten. SARPAC Clinical Trial of Leukine® in Hospitalized COVID-19 Patients, Demonstrates Significant Improvement in Lung Function 26/02/2021 Partner Therapeutics, Inc. (PTx) announced top-line results today of the investigator-led SARPAC (Sargramostim in Patients with Acute Hypoxic Respiratory Failure and Acute COVID-19) study of inhaled Leukine (sargramostim, rhuGM-CSF) in hospitalized COVID-19 patients. Leuven study shows immune reaction in the lungs of seriously ill COVID-19-patients 22/01/2021 UZ Leuven, KU Leuven researchers and the VIB have examined the immune reaction in COVID-19-patients admitted to the hospital for pneumonia. Detailed analyses of the lung fluid showed new factors that play a role in the excessive immune reactions against the virus in seriously ill patients. Diether Lambrechts receives ERC Proof of Concept grant 10/01/2020 Prof. Diether Lambrechts (VIB-KU Leuven Center for Cancer Biology) has been awarded a Proof of Concept grant by the European Research Council. With this grant, he will be able to explore the use of DNA methylation patterns detectable in tumor DNA that circulates in the blood as predictive marker for resistance against cancer treatments. Revolutionary molecular diagnostic cancer test 24/11/2018 Biocartis launched a fast, accurate msi assay on its idylla™ platform, offering the Potential to predict effective cancer treatment options. Scientists identify chromosomal instability as a novel predictive biomarker for cancer drug Avastin 10/10/2018 Following a recent publication in the leading cancer journal Journal of Clinical Oncology RCSI and international collaborators within the ANGIOPREDICT research consortium have now further revealed chromosomal instability (where whole human chromosomes or parts of chromosomes are duplicated or deleted) may predict which patients benefit most from the use of a key drug to treat colorectal cancer (Avastin). By predicting the patients that would not benefit from Avastin, individuals could be spared the side-effects of this particular drug therapy, and are more likely to receive an optimal treatment with a minimum of delay, while reducing cost of care. Biocartis launches innovative Idylla™ MSI Assay 17/07/2018 Idylla™ MSI Assay further strengthens Biocartis’ test menu and offers opportunities to enter the immuno-oncology testing market. Scientists create a complete atlas of lung tumor cells 09/07/2018 Researchers from VIB, Leuven University and University Hospital Leuven studied thousands of healthy and cancerous lung cells to create the first comprehensive atlas of lung tumor cells. Their results reveal that tumors are much more complex than previously appreciated, distinguishing 52 different types of cells. This new information can be used to identify new research lines for treatment. The results of the study will be published in the leading journal Nature Medicine. Major study of genetics of breast cancer provides clues to mechanisms behind the disease 23/10/2017 Seventy-two new genetic variants that contribute to the risk of developing breast cancer have been identified by a major international collaboration involving hundreds of researchers worldwide. VIB pushes the boundaries of science to develop new diagnostic tools 27/07/2017 Greater knowledge of molecular mechanisms and novel bio-analytical methods lead to more efficient and accurate diagnostics. With their world-leading strengths in molecular research and biotechnology, various VIB labs are paving the way for novel diagnostic tools that will ultimately reduce disease burden and save lives by making disease diagnosis better, faster and more flexible. The proof is in the partnership: three recent collaborations between VIB, university hospitals and diagnostics industry leaders highlight just how critical molecular science at VIB is to the development of cutting-edge diagnostic technology. Pagination Current page 1 Page 2 Next page Next ›
COVAID-studie trekt werkzaamheid van reumageneesmiddelen bij gehospitaliseerde COVID-19-patienten in twijfel 15/03/2021 Een studie gecoördineerd door het UZ Gent en gefinancierd door het KCE Trials Programme van het Federaal Kenniscentrum voor de Gezondheidszorg (KCE) toont aan dat de reumageneesmiddelen tocilizumab, siltuximab en anakinra geen impact hebben bij de behandeling van Belgische gehospitaliseerde COVID-19-patiënten.
SARPAC Clinical Trial of Leukine® in Hospitalized COVID-19 Patients, Demonstrates Significant Improvement in Lung Function 26/02/2021 Partner Therapeutics, Inc. (PTx) announced top-line results today of the investigator-led SARPAC (Sargramostim in Patients with Acute Hypoxic Respiratory Failure and Acute COVID-19) study of inhaled Leukine (sargramostim, rhuGM-CSF) in hospitalized COVID-19 patients.
Leuven study shows immune reaction in the lungs of seriously ill COVID-19-patients 22/01/2021 UZ Leuven, KU Leuven researchers and the VIB have examined the immune reaction in COVID-19-patients admitted to the hospital for pneumonia. Detailed analyses of the lung fluid showed new factors that play a role in the excessive immune reactions against the virus in seriously ill patients.
Diether Lambrechts receives ERC Proof of Concept grant 10/01/2020 Prof. Diether Lambrechts (VIB-KU Leuven Center for Cancer Biology) has been awarded a Proof of Concept grant by the European Research Council. With this grant, he will be able to explore the use of DNA methylation patterns detectable in tumor DNA that circulates in the blood as predictive marker for resistance against cancer treatments.
Revolutionary molecular diagnostic cancer test 24/11/2018 Biocartis launched a fast, accurate msi assay on its idylla™ platform, offering the Potential to predict effective cancer treatment options.
Scientists identify chromosomal instability as a novel predictive biomarker for cancer drug Avastin 10/10/2018 Following a recent publication in the leading cancer journal Journal of Clinical Oncology RCSI and international collaborators within the ANGIOPREDICT research consortium have now further revealed chromosomal instability (where whole human chromosomes or parts of chromosomes are duplicated or deleted) may predict which patients benefit most from the use of a key drug to treat colorectal cancer (Avastin). By predicting the patients that would not benefit from Avastin, individuals could be spared the side-effects of this particular drug therapy, and are more likely to receive an optimal treatment with a minimum of delay, while reducing cost of care.
Biocartis launches innovative Idylla™ MSI Assay 17/07/2018 Idylla™ MSI Assay further strengthens Biocartis’ test menu and offers opportunities to enter the immuno-oncology testing market.
Scientists create a complete atlas of lung tumor cells 09/07/2018 Researchers from VIB, Leuven University and University Hospital Leuven studied thousands of healthy and cancerous lung cells to create the first comprehensive atlas of lung tumor cells. Their results reveal that tumors are much more complex than previously appreciated, distinguishing 52 different types of cells. This new information can be used to identify new research lines for treatment. The results of the study will be published in the leading journal Nature Medicine.
Major study of genetics of breast cancer provides clues to mechanisms behind the disease 23/10/2017 Seventy-two new genetic variants that contribute to the risk of developing breast cancer have been identified by a major international collaboration involving hundreds of researchers worldwide.
VIB pushes the boundaries of science to develop new diagnostic tools 27/07/2017 Greater knowledge of molecular mechanisms and novel bio-analytical methods lead to more efficient and accurate diagnostics. With their world-leading strengths in molecular research and biotechnology, various VIB labs are paving the way for novel diagnostic tools that will ultimately reduce disease burden and save lives by making disease diagnosis better, faster and more flexible. The proof is in the partnership: three recent collaborations between VIB, university hospitals and diagnostics industry leaders highlight just how critical molecular science at VIB is to the development of cutting-edge diagnostic technology.
